About BioLife Solutions:
The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife’s biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife’s enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services.
- Price Data
- Markets
- SEC Filings
- Analysts
- Presentations
About BioLife Solutions Addressable Markets
- In July 2015, Frost & Sullivan forecasted that the stem cell therapy market is expected to be worth $40 billion by 2020 and $180 billion by 2030.
- Pharmaceutical Commerce estimates that in 2015, $10 billion was spent on cold chain logistics of pharmaceuticals, with $7 billion for transportation and $3 billion for specialized packaging and instrumentation. BioLife's addressable market is comprised of the demand for small payload shipping containers and related temperature monitoring and location tracking devices.
- Global Industry Analysts, Inc. estimates in their September 2015 Organ Preservation Solutions, A Global Strategic Business Report that the worldwide demand for organ cold storage solutions was $85.5 million in 2014, and is expected to grow 109% to over $175 million in 2020.
Read about our markets:
Firm | Analyst |
Janney | Paul Knight, CFA |
Maxim Group | Jason Kolbert Jason McCarthy, Ph.D. |
BioLife Solutions, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding BioLife Solutions, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of BioLife Solutions, Inc. or its management. BioLife Solutions, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.